Skip to main content
Research
  1. Queen Mary University of London
  2. Research
  3. Publications

Publications: DR Joseph Gibbons

Back to Search
Abhishek A, Peckham N, Pade C, Gibbons JM, Cureton L, Reynolds CJ, Francis A, Barber V et al. ( 2025 ) . Temporary 2-week suspension of methotrexate treatment to enhance COVID-19 vaccine response in people with immune-mediated inflammatory diseases: the VROOM RCT . Efficacy and Mechanism Evaluation1 - 42 .
Abhishek A, Peckham N, Pade C, Gibbons JM, Cureton L, Reynolds CJ, Francis A, Barber V et al. ( 2025 ) . Effect of a 2-week interruption in methotrexate treatment on COVID-19 vaccine response in people with immune-mediated inflammatory diseases (VROOM study): a randomised, open label, superiority trial . Efficacy and Mechanism Evaluation vol. 12 , ( 05 ) 47 - 48 .
Abhishek A, Peckham N, Pade C, Gibbons JM, Cureton L, Reynolds CJ, Francis A, Barber V et al. ( 2025 ) . Effect of a 2-week interruption in methotrexate treatment versus continued treatment on COVID-19 booster vaccine immunity in adults with inflammatory conditions (VROOM study): a randomised, open label, superiority trial . Efficacy and Mechanism Evaluation vol. 12 , ( 05 ) 45 - 46 .
Abhishek A, Peckham N, Pade C, Gibbons JM, Cureton L, Reynolds CJ, Francis A, Barber V et al. ( 2025 ) . Effects of temporarily suspending low-dose methotrexate treatment for 2 weeks after SARS-CoV-2 vaccine booster on vaccine response in immunosuppressed adults with inflammatory conditions: protocol for a multicentre randomised controlled trial and nested mechanistic substudy (Vaccine Response On/Off Methotrexate (VROOM) study) . Efficacy and Mechanism Evaluation vol. 12 , ( 05 ) 43 - 44 .
Chambers ES, Cai W, Vivaldi G, Jolliffe DA, Perdek N, Li W, Faustini SE, Gibbons JM et al. ( 2024 ) . Influence of individuals’ determinants including vaccine type on cellular and humoral responses to SARS-CoV-2 vaccination . npj Vaccines vol. 9 , ( 1 )
Abhishek A, Peckham N, Pade C, Gibbons JM, Cureton L, Francis A, Barber V, Williams JAE et al. ( 2023 ) . Effect of a 2-week interruption in methotrexate treatment on COVID-19 vaccine response in people with immune-mediated inflammatory diseases (VROOM study): a randomised, open label, superiority trial . The Lancet Rheumatology vol. 6 , ( 2 ) e92 - e104 .
Altmann DM, Reynolds CJ, Joy G, Otter AD, Gibbons JM, Pade C, Swadling L, Maini MK et al. ( 2023 ) . Persistent symptoms after COVID-19 are not associated with differential SARS-CoV-2 antibody or T cell immunity . Nature Communications vol. 14 , ( 1 )
Gokani B, Sacoor S, Leisegang GR, Ogunkolade W, Bibi A, Grigoriadou S, Pade C, Gibbons J et al. ( 2023 ) . Behçet's patients' response to COVID-19 vaccination . Clinical Immunology vol. 255 ,
Miyashita L, Foley G, Semple S, Gibbons JM, Pade C, McKnight Á, Grigg J ( 2023 ) . Curbside particulate matter and susceptibility to SARS–CoV-2 infection . Journal of Allergy and Clinical Immunology Global vol. 2 , ( 4 )
Milighetti M, Peng Y, Tan C, Mark M, Nageswaran G, Byrne S, Ronel T, Peacock T et al. ( 2023 ) . Large clones of pre-existing T cells drive early immunity against SARS-COV-2 and LCMV infection . iScience vol. 26 , ( 6 )
Milojkovic D, Reynolds CJ, Sandoval DM, Pieper FP, Liu S, Pade C, Gibbons JM, McKnight Á et al. ( 2022 ) . COVID-19 vaccine boosted immunity against Omicron in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors . Leukemia vol. 37 , ( 1 ) 244 - 247 .
Captur G, Moon JC, Topriceanu C-C, Joy G, Swadling L, Hallqvist J, Doykov I, Patel N et al. ( 2022 ) . Plasma proteomic signature predicts who will get persistent symptoms following SARS-CoV-2 infection . EBioMedicine vol. 85 ,
Jolliffe DA, Vivaldi G, Chambers ES, Cai W, Li W, Faustini SE, Gibbons JM, Pade C et al. ( 2022 ) . Vitamin D Supplementation Does Not Influence SARS-CoV-2 Vaccine Efficacy or Immunogenicity: Sub-Studies Nested within the CORONAVIT Randomised Controlled Trial . Nutrients vol. 14 , ( 18 )
Doykov I, Baldwin T, Spiewak J, Gilmour KC, Gibbons JM, Pade C, Reynolds CJ, McKnight Á et al. ( 2022 ) . Quantitative, multiplexed, targeted proteomics for ascertaining variant specific SARS-CoV-2 antibody response . Cell Reports Methods vol. 2 , ( 9 )
Vivaldi G, Jolliffe DA, Faustini S, Shields AM, Holt H, Perdek N, Talaei M, Tydeman F et al. ( 2022 ) . Correlation Between Postvaccination Anti-Spike Antibody Titers and Protection Against Breakthrough Severe Acute Respiratory Syndrome Coronavirus 2 Infection: A Population-Based Longitudinal Study . Journal of Infectious Diseases vol. 226 , ( 11 ) 1903 - 1908 .
Reynolds CJ, Pade C, Gibbons JM, Otter AD, Lin K-M, Muñoz Sandoval D, Pieper FP, Butler DK et al. ( 2022 ) . Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure . Science vol. 377 , ( 6603 )
Riddell AC, Kele B, Harris K, Bible J, Murphy M, Dakshina S, Storey N, Owoyemi D et al. ( 2022 ) . Generation of Novel Severe Acute Respiratory Syndrome Coronavirus 2 Variants on the B.1.1.7 Lineage in 3 Patients With Advanced Human Immunodeficiency Virus-1 Disease . Clinical Infectious Diseases vol. 75 , ( 11 ) 2016 - 2018 .
Astbury S, Reynolds CJ, Butler DK, Muñoz‐Sandoval DC, Lin K, Pieper FP, Otter A, Kouraki A et al. ( 2022 ) . HLA‐DR polymorphism in SARS‐CoV‐2 infection and susceptibility to symptomatic COVID‐19 . Immunology vol. 166 , ( 1 ) 68 - 77 .
Chandran A, Rosenheim J, Nageswaran G, Swadling L, Pollara G, Gupta RK, Burton AR, Guerra-Assunção JA et al. ( 2022 ) . Rapid synchronous type 1 IFN and virus-specific T cell responses characterize first wave non-severe SARS-CoV-2 infections . Cell Reports Medicine vol. 3 , ( 3 )
Usai C, Gibbons JM, Pade C, Li W, Jacobs SRM, McKnight Á, Kennedy PTF, Gill US ( 2022 ) . The β-NGF/TrkA Signalling Pathway Is Associated With the Production of Anti-Nucleoprotein IgG in Convalescent COVID-19 . Frontiers in Immunology vol. 12 ,
Miyashita L, Foley G, Semple S, Gibbons J, Pade C, Mcknight A, Grigg J ( 2022 ) . Kerbside Particulate Matter and Susceptibility to SARS-CoV-2 Infection .
Reynolds CJ, Gibbons JM, Pade C, Lin K-M, Sandoval DM, Pieper F, Butler DK, Liu S et al. ( 2021 ) . Heterologous infection and vaccination shapes immunity against SARS-CoV-2 variants . Science vol. 375 , ( 6577 ) 183 - 192 .
Swadling L, Diniz MO, Schmidt NM, Amin OE, Chandran A, Shaw E, Pade C, Gibbons JM et al. ( 2021 ) . Pre-existing polymerase-specific T cells expand in abortive seronegative SARS-CoV-2 . Nature
Gupta RK, Rosenheim J, Bell LC, Chandran A, Guerra-Assuncao JA, Pollara G, Whelan M, Artico J et al. ( 2021 ) . Blood transcriptional biomarkers of acute viral infection for detection of pre-symptomatic SARS-CoV-2 infection: a nested, case-control diagnostic accuracy study . Lancet Microbe vol. 2 , ( 10 ) e508 - e517 .
Joy G, Artico J, Kurdi H, Seraphim A, Lau C, Thornton GD, Oliveira MF, Adam RD et al. ( 2021 ) . Prospective Case-Control Study of Cardiovascular Abnormalities 6 Months Following Mild COVID-19 in Healthcare Workers . JACC Cardiovascular Imaging vol. 14 , ( 11 ) 2155 - 2166 .
Reynolds CJ, Pade C, Gibbons JM, Butler DK, Otter AD, Menacho K, Fontana M, Smit A et al. ( 2021 ) . Prior SARS-CoV-2 infection rescues B and T cell responses to variants after first vaccine dose . Science vol. 372 , ( 6549 ) 1418 - 1423 .
Manisty C, Treibel TA, Jensen M, Semper A, Joy G, Gupta RK, Cutino-Moguel T, Andiapen M et al. ( 2021 ) . Time series analysis and mechanistic modelling of heterogeneity and sero-reversion in antibody responses to mild SARS‑CoV-2 infection . EBioMedicine vol. 65 ,
Reynolds CJ, Swadling L, Gibbons JM, Pade C, Jensen MP, Diniz MO, Schmidt NM, Butler DK et al. ( 2020 ) . Discordant neutralizing antibody and T cell responses in asymptomatic and mild SARS-CoV-2 infection . Science Immunology vol. 5 , ( 54 )
Augusto JB, Menacho K, Andiapen M, Bowles R, Burton M, Welch S, Bhuva AN, Seraphim A et al. ( 2020 ) . Healthcare Workers Bioresource: Study outline and baseline characteristics of a prospective healthcare worker cohort to study immune protection and pathogenesis in COVID-19 . Wellcome Open Research vol. 5 , 179 - 179 .
Gibbons JM, Marno KM, Pike R, Lee W-YJ, Jones CE, Ogunkolade BW, Pardieu C, Bryan A et al. ( 2020 ) . HIV-1 Accessory Protein Vpr Interacts with REAF/RPRD2 To Mitigate Its Antiviral Activity . Journal of Virology vol. 94 , ( 4 ) 10.1128/jvi.01591 - 10.1128/jvi.01519 .
Gibbons J, Marno K, Pike R, Lee J, Jones C, Ogunkolade W, Pardieu C, Warnes G et al. ( 2019 ) . HIV-1 Vpr accessory protein interacts with REAF and mitigates its associated anti-viral activity . Access Microbiology vol. 1 , ( 1A )
Gibbons J, Lee W-YJ, McKnight Á ( 2019 ) . HIV-1 infectivity of cells is enhanced at mitosis: a role for Vpr? . Access Microbiology vol. 1 , ( 1A )
Manisty C, Treibel T, Jensen M, Semper A, Joy G, Gupta R, Cutino-Moguel T, Andiapen M et al. . Characterising heterogeneity and sero-reversion in antibody responses to mild SARS⍰CoV-2 infection: a cohort study using time series analysis and mechanistic modelling .
Vivaldi G, Jolliffe DA, Faustini S, Holt H, Perdek N, Talaei M, Tydeman F, Chambers ES et al. . Correlation between post-vaccination titres of combined IgG, IgA, and IgM anti-Spike antibodies and protection against breakthrough SARS-CoV-2 infection: a population-based longitudinal study (COVIDENCE UK) .
Riddell AC, Kele B, Harris K, Bible J, Murphy M, Dakshina S, Storey N, Owoyemi D et al. . Generation of novel SARS-CoV-2 variants on B.1.1.7 lineage in three patients with advanced HIV disease .
Gibbons JM, Marno KM, Pike R, Lee W-YJ, Jones CE, Ogunkolade BW, Pardieu C, Bryan A et al. . HIV-1 accessory protein Vpr interacts with REAF/RPRD2 to mitigate its antiviral activity .
Reynolds CJ, Swadling L, Gibbons JM, Pade C, Jensen MP, Diniz MO, Schmidt NM, Butler D et al. . Healthcare workers with mild / asymptomatic SARS-CoV-2 infection show T cell responses and neutralising antibodies after the first wave .
Chambers ES, Cai W, Vivaldi G, Jolliffe DA, Perdek N, Li W, Faustini SE, Gibbons JM et al. . Influence of age, sex, body habitus, vaccine type and anti-S serostatus on cellular and humoral responses to SARS-CoV-2 vaccination .
Jolliffe DA, Vivaldi G, Chambers ES, Cai W, Li W, Faustini SE, Gibbons JM, Pade C et al. . Influence of vitamin D supplementation on SARS-CoV-2 vaccine efficacy and immunogenicity .
Milighetti M, Peng Y, Tan C, Mark M, Nageswaran G, Byrne S, Ronel T, Peacock T et al. . Large clones of pre-existing T cells drive early immunity against SARS-COV-2 and LCMV infection .
Chandran A, Rosenheim J, Nageswaran G, Swadling L, Pollara G, Gupta RK, Guerra-Assuncao JA, Woolston A et al. . Non-severe SARS-CoV-2 infection is characterised by very early T cell proliferation independent of type 1 interferon responses and distinct from other acute respiratory viruses .
Altmann D, Reynolds C, Joy G, Otter A, Gibbons J, Pade C, Swadling L, Maini M et al. . Persistent symptoms after COVID-19 during the first wave are not associated with differential immunity to SARS-CoV-2 .
Swadling L, Diniz MO, Schmidt NM, Amin OE, Chandran A, Shaw E, Pade C, Gibbons JM et al. . Pre-existing polymerase-specific T cells expand in abortive seronegative SARS-CoV-2 infection .
Griffith S, Muir L, Suchanek O, Hope J, Pade C, Gibbons JM, Tuong ZK, Fung A et al. . Preservation of memory B cell homeostasis in an individual producing broadly neutralising antibodies against HIV-1 .
Doykov I, Spiewak J, Gilmour KC, Gibbons JM, Pade C, McKnight Á, Noursadeghi M, Maini MK et al. . Quantitative, multiplexed, targeted proteomics for ascertaining variant specific SARS-CoV-2 antibody response .
Usai C, Gibbons JM, Pade C, Li W, Jacobs SRM, McKnight Á, Kennedy PTF, Gill US . The β-NGF/TrkA signalling pathway is associated with the production of anti- nucleoprotein IgG in convalescent COVID-19 .
Back to Search